Donate

Radiotherapy Might Not Extend Survival In Men With Prostate Cancer Who Are Under 70 Years Old

Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone [...]

Analyzing the Analysis – Is Surgery Superior to Radiotherapy? No, Despite the Results from A Large Canadian Study

It is a little out of the normal scope of this blog, but a recent prostate cancer study from Canada has received a lot of buzz and needs some commentary and analysis. The study concluded that for men who are diagnosed with local prostate cancer (still confined in the gland) live longer if they have [...]

A Review of the Literature on the Treatment of Oligometastasis in Prostate Cancer

Oligometastasis can be described as a state of limited metastatic disease following failed primary treatment or even prostate cancer as it is first diagnosed. Many doctors believe that it is amenable to aggressive local therapy to achieve long-term survival. In a review designed to explore the role of ablative radiotherapy and surgical management of oligo-metastatic [...]

Adding Radiotherapy to ADT Increases Survival for a Man Diagnosed with Locally Advanced Prostate Cancer

Men with locally advanced prostate cancer have a better survival chance if they receive radiotherapy along with androgen deprivation therapy (ADT). This data was presented at the recent American Society of Clinical Oncology (ASCO) 2012 conference. Professor Malcom Mason from Whales University discussed a trial he conducted that demonstrated that for a man diagnosed with [...]

Study Shows that Six Months of Neoadjuvant ADT Significantly Reduces Mortality in Locally Advanced Prostate Cancer

Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer. […]

Time Between Treatment And PSA Recurrence Predicts Death From Prostate Cancer

According to a study last year at Fox Chase Cancer Center, men whose prostate specific antigen (PSA) rise within 18 months of having primary radiotherapy are more likely to develop advanced prostate cancer and die of their disease. […]

Salvage Radical Prostatectomy After Failed Radiotherapy Can Work

A small study out of the Department of Urology, University of Rome, Rome, Italy has demonstrated that a salvage radical prostatectomy is a reasonable treatment option for men with locally recurrent prostate cancer after external beam radiotherapy failure. Despite the traditional belief that surgery can not follow failed radiation treatment, this argument against initial radiotherapy [...]

By |2009-07-06T06:22:40-04:00July 6th, 2009|Advanced Prostate Cancer, Uncategorized|0 Comments

Radiation Plus Hormone Therapy Cuts Prostate Cancer Mortality by 50% in men with Locally Advanced Disease

Investigators have reported, at the American Society for Therapeutic Radiation and Oncology (ASTRO) 50th Annual Meeting, that when radiation is added to anti-androgen therapy (ADT), survival rates are increased by 50% in men receiving only ADT. "This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer [...]

Antioxidant Supplements May Lessen Benefit Of Radiation And Chemotherapy

During radiation and chemotherapy, cancer patients including prostate cancer patients, should avoid the routine use of antioxidant supplements unless approved by their doctor. Supplements may reduce the anticancer benefits of therapy, researchers concluded in a commentary published online in the Journal of the National Cancer Institute. Radiation and Taxotere used for advanced prostate cancer therapy [...]

Go to Top